Shirinkin, Vadim
for the ASTRUM-005 Study Group
3 papers on CoChatORCID 0000-0002-2475-9500
Most cited papers
- Verified
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Swain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., et al. (2020) · The Lancet Oncology
HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Cited by 922
- Verified
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial
Cheng, Y., Han, L., Wu, L., Chen, J., Sun, H., Wen, G., Ji, Y., Dvorkin, M., Shi, J., Pan, Z., et al. (2022) · JAMA
Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers
Cited by 492
- Verified
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., et al. (2014) · Annals of Oncology
HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Cited by 177
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free